Search Page

1

Cite

Share

Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development.

Karakontaki FV, Panselinas ES, Polychronopoulos VS, Tzioufas AG. Karakontaki FV, et al. Autoimmun Rev. 2021 Feb;20(2):102742. doi: 10.1016/j.autrev.2020.102742. Epub 2020 Dec 14. Autoimmun Rev. 2021. PMID: 33333235 Review.

Cite

Share

2

Cite

Share

Driving-Related Neuropsychological Performance in Stable COPD Patients.

Karakontaki F, Gennimata SA, Palamidas AF, Anagnostakos T, Kosmas EN, Stalikas A, Papageorgiou C, Koulouris NG. Karakontaki F, et al. Pulm Med. 2013;2013:297371. doi: 10.1155/2013/297371. Epub 2013 Feb 4. Pulm Med. 2013. PMID: 23431438 Free PMC article.

Cite

Share

3

Cite

Share

Prediction of hospitalization stay in COPD exacerbations: the AECOPD-F score.

Diamantea F, Kostikas K, Bartziokas K, Karakontaki F, Tsikrika S, Pouriki S, Polychronopoulos V, Karagiannidis N, Haniotou A, Papaioannou AI. Diamantea F, et al. Among authors: karakontaki f. Respir Care. 2014 Nov;59(11):1679-86. doi: 10.4187/respcare.03171. Epub 2014 Jun 24. Respir Care. 2014. PMID: 24962226 Free article.

Cite

Share

4

Cite

Share

Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk?

Papaioannou AI, Bartziokas K, Loukides S, Tsikrika S, Karakontaki F, Haniotou A, Papiris S, Stolz D, Kostikas K. Papaioannou AI, et al. Among authors: karakontaki f. Eur Respir J. 2015 Sep;46(3):846-9. doi: 10.1183/09031936.00237014. Epub 2015 Apr 16. Eur Respir J. 2015. PMID: 25882807 Free article. No abstract available.

Cite

Share

5

Cite

Share

How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study.

Kampolis CF, Venetsanopoulou AI, Karakontaki F, Polychronopoulos V, Vlachoyiannopoulos P, Tzioufas AG. Kampolis CF, et al. Among authors: karakontaki f. Autoimmun Rev. 2018 Nov;17(11):1124-1133. doi: 10.1016/j.autrev.2018.06.004. Epub 2018 Sep 11. Autoimmun Rev. 2018. PMID: 30213691

Cite

Share

6

Cite

Share

Collateral damage: depressive symptoms in the partners of COPD patients.

Papaioannou AI, Tsikrika S, Bartziokas K, Karakontaki F, Kastanakis E, Diamantea F, Haniotou A, Papiris S, Polychronopoulos V, Loukides S, Kostikas K. Papaioannou AI, et al. Among authors: karakontaki f. Lung. 2014 Aug;192(4):519-24. doi: 10.1007/s00408-014-9595-4. Epub 2014 May 11. Lung. 2014. PMID: 24816968

Cite

Share

7

Cite

Share

The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations.

Papaioannou AI, Bartziokas K, Tsikrika S, Karakontaki F, Kastanakis E, Banya W, Haniotou A, Papiris S, Loukides S, Polychronopoulos V, Kostikas K. Papaioannou AI, et al. Among authors: karakontaki f. Eur Respir J. 2013 Apr;41(4):815-23. doi: 10.1183/09031936.00013112. Epub 2012 Aug 9. Eur Respir J. 2013. PMID: 22878874 Free article.

Cite

Share

8

Cite

Share

Impact of hemodialysis on dyspnea and lung function in end stage kidney disease patients.

Palamidas AF, Gennimata SA, Karakontaki F, Kaltsakas G, Papantoniou I, Koutsoukou A, Milic-Emili J, Vlahakos DV, Koulouris NG. Palamidas AF, et al. Among authors: karakontaki f. Biomed Res Int. 2014;2014:212751. doi: 10.1155/2014/212751. Epub 2014 May 8. Biomed Res Int. 2014. PMID: 24895552 Free PMC article.

Cite

Share

9

Cite

Share

Pathophysiology of evolution of small airways disease to overt COPD.

Gennimata SA, Palamidas A, Karakontaki F, Kosmas EN, Koutsoukou A, Loukides S, Koulouris NG. Gennimata SA, et al. Among authors: karakontaki f. COPD. 2010 Aug;7(4):269-75. doi: 10.3109/15412555.2010.497515. COPD. 2010. PMID: 20673036

Cite

Share